pipette
ESEspañol

An ulcerative colitis taxonomy defined by individual patient-reported response trajectories

Stefan Schreiber, Vijay Yajnik, Cenfu Wei, Maria D. Paraskevopoulou, Saman Farahmand, Jie Cheng, Katherine H. Simpson, Zitong Lin, Christian Agboton, Pratik Panchal, Banishree Saha, Ninfa M. Candela, Joshua Brown, Isabella Marie Peshek, Frida Chavez, Libeth Rosas, Alan Robinson, Gursimran Singh Kochhar, Aakash Desai, Franziska Kimmig, Philip C Rosenstiel, Paresh Thakker, Parambir Singh Dulai

Peer-reviewed journalReal-world use

In the authors' words

Abstract A barrier to precision medicine for ulcerative colitis (UC) is the inability to predict and mechanistically explain treatment responses. Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor). Validation in a second phase 3 trial of 576 participants linked PRO-defined vedolizumab trajectories to long-term disease complications. Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1 + macrophages and endothelial cells. In two separate real-world cohorts of 4,981 and 3,854 patients with UC, concomitant use of renin–angiotensin system inhibitors (modulators of vascular inflammation) was associated with reduced long-term complications for vedolizumab but not anticytokine therapies. These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.

Main resultLimitation the authors admit

Appeared: Wednesday, November 11. Nature Medicine. Peer-reviewed journal.

DOI: 10.1038/s41591-026-04741-8